Can a simple pill stop a hidden virus after cancer treatment?

NCT ID NCT06575374

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from reactivating in people who have received a type of CAR T-cell therapy called axicabtagene ciloleucel. CMV is a common virus that can cause serious illness when the immune system is weakened. The trial will enroll 36 adults who are CMV-positive and scheduled for this therapy, giving them letermovir by mouth or IV. The main goal is to see if the drug is safe and reduces CMV reactivation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letermovir
What this could lead to: If it works, this could offer a way to prevent a common viral complication in patients receiving CAR T-cell therapy.
What could go wrong: This is a small, early-phase pilot trial with only 36 participants, so results may not apply broadly. Side effects are possible, and the drug may not prevent CMV as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELL THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CELL THERAPY

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.